Ann Hartry

1.0k total citations
36 papers, 682 citations indexed

About

Ann Hartry is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Clinical Psychology. According to data from OpenAlex, Ann Hartry has authored 36 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Psychiatry and Mental health, 8 papers in Economics and Econometrics and 7 papers in Clinical Psychology. Recurrent topics in Ann Hartry's work include Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (14 papers) and Dementia and Cognitive Impairment Research (11 papers). Ann Hartry is often cited by papers focused on Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (14 papers) and Dementia and Cognitive Impairment Research (11 papers). Ann Hartry collaborates with scholars based in United States, Denmark and Spain. Ann Hartry's co-authors include Mallik Greene, Tingjian Yan, Michael S. Broder, Eunice Chang, Maëlys Touya, Myrlene Sanon Aigbogun, Ross A. Baker, Ruth A. Duffy, Rachel Halpern and Douglas W. Mapel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Journal of Affective Disorders.

In The Last Decade

Ann Hartry

34 papers receiving 673 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Hartry United States 15 488 126 110 87 67 36 682
Ola Granström Sweden 8 474 1.0× 190 1.5× 77 0.7× 56 0.6× 84 1.3× 13 722
Amy Grogg United States 13 865 1.8× 201 1.6× 117 1.1× 79 0.9× 121 1.8× 26 1.2k
Art Walaszek United States 10 556 1.1× 179 1.4× 54 0.5× 69 0.8× 116 1.7× 32 865
Julie Locklear United States 14 1.0k 2.1× 356 2.8× 138 1.3× 144 1.7× 131 2.0× 38 1.4k
Anne M. Frederickson United States 10 687 1.4× 188 1.5× 27 0.2× 61 0.7× 42 0.6× 11 837
Hung‐Yu Chan Taiwan 17 443 0.9× 168 1.3× 36 0.3× 94 1.1× 61 0.9× 57 789
Timothy Peters-Strickland United States 16 680 1.4× 173 1.4× 99 0.9× 93 1.1× 171 2.6× 43 893
Leah Gillon United States 14 491 1.0× 289 2.3× 76 0.7× 52 0.6× 62 0.9× 16 991
Hany G El-Sayeh United Kingdom 11 695 1.4× 221 1.8× 86 0.8× 134 1.5× 183 2.7× 22 931
M. Bouhassira France 13 262 0.5× 94 0.7× 35 0.3× 148 1.7× 47 0.7× 25 532

Countries citing papers authored by Ann Hartry

Since Specialization
Citations

This map shows the geographic impact of Ann Hartry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Hartry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Hartry more than expected).

Fields of papers citing papers by Ann Hartry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Hartry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Hartry. The network helps show where Ann Hartry may publish in the future.

Co-authorship network of co-authors of Ann Hartry

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Hartry. A scholar is included among the top collaborators of Ann Hartry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Hartry. Ann Hartry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DeMuro, Carla, Emily Bratlee‐Whitaker, Ann Hartry, et al.. (2024). Measuring What Matters Most to People Living with Alzheimer’s Disease and Care Partners: What Matters Most Quantitative Research Development. Alzheimer s & Dementia. 20(S4). 1 indexed citations
2.
Zur, Richard M., et al.. (2023). Estimating prevalence of early symptomatic Alzheimer's disease in the United States. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 15(4). e12497–e12497. 1 indexed citations
3.
Winner, Paul, Ann Hartry, Thomas Brevig, et al.. (2021). Patient Preference for Early Onset of Efficacy in Migraine Prevention (1749). Neurology. 96(15_supplement). 1 indexed citations
4.
Aigbogun, Myrlene Sanon, Martin Cloutier, Marjolaine Gauthier‐Loiselle, et al.. (2020). Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. Journal of Alzheimer s Disease. 77(3). 1181–1194. 16 indexed citations
5.
DiBenedetti, Dana, Christina Slota, George Vradenburg, et al.. (2020). Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimer s Research & Therapy. 12(1). 90–90. 53 indexed citations
6.
Rubino, Annalisa, Michael L. Ganz, Miriam C. Fenton, et al.. (2020). Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia. JAMA Network Open. 3(4). e203630–e203630. 19 indexed citations
7.
Greene, Mallik, et al.. (2019). <p>Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder</p>. ClinicoEconomics and Outcomes Research. Volume 11. 741–755. 4 indexed citations
8.
Broder, Michael S., Mallik Greene, Tingjian Yan, et al.. (2019). Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment. Clinical Therapeutics. 41(2). 221–232. 6 indexed citations
9.
Anatchkova, Milena, Ann Hartry, Ruth A. Duffy, et al.. (2019). Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. International Psychogeriatrics. 31(9). 1305–1318. 21 indexed citations
10.
11.
12.
Yan, Tingjian, Mallik Greene, Eunice Chang, et al.. (2018). Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. Journal of Comparative Effectiveness Research. 8(4). 217–227. 8 indexed citations
13.
14.
Coste, F, Lin Xie, Myrlene Sanon Aigbogun, et al.. (2017). A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients. Neurology and Therapy. 6(1). 131–144. 22 indexed citations
15.
Llorca, Pierre‐Michel, Christophe Lançon, Ann Hartry, et al.. (2017). Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 17(1). 67–67. 21 indexed citations
16.
Greene, Mallik, Tingjian Yan, Eunice Chang, et al.. (2017). Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Journal of Medical Economics. 21(2). 127–134. 139 indexed citations
17.
Sussman, Matthew, Jeffrey Yu, Siddhesh Kamat, et al.. (2016). Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. Journal of Affective Disorders. 207. 54–62. 8 indexed citations
18.
Sapin, Christophe, Ann Hartry, Siddhesh Kamat, et al.. (2016). Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context. 5. 1–8. 8 indexed citations
19.
Roberts, Melissa, et al.. (2013). Chronic Pain and Pain Medication Use in Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study. Annals of the American Thoracic Society. 10(4). 290–298. 57 indexed citations
20.
Berner, Todd, et al.. (2011). A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain.. PubMed. 36(3). 139–44. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ola Granström Breakdown of academic impact, for papers by Amy Grogg Breakdown of academic impact, for papers by Art Walaszek Breakdown of academic impact, for papers by Julie Locklear Breakdown of academic impact, for papers by Anne M. Frederickson Breakdown of academic impact, for papers by Hung‐Yu Chan Breakdown of academic impact, for papers by Timothy Peters-Strickland Breakdown of academic impact, for papers by Leah Gillon Breakdown of academic impact, for papers by Hany G El-Sayeh Breakdown of academic impact, for papers by M. Bouhassira
Rankless by CCL
2026